RAS and BRAF mutated (MT) colorectal cancers (CRC) occur in >60% of CRC patients and are associated with poor outcome. Although the therapeutic armamentarium of CRC has increased over the last 2 decades, there are subgroups of RAS and BRAFMT CRC in urgent need for novel treatments.

The research is focused on the identification of novel targets and pathways that are particularly relevant to drug resistance in the context of RAS/BRAFMT at the bench and applying this at the bedside.